Filing Flows › Twist Bioscience (TWST) › Q1 FY26
Twist Bioscience (TWST) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Feb 2, 2026
Twist Bioscience (TWST) reported revenue of $104M for the first quarter fiscal 2026 (Q1 FY26), +17% from a year earlier and +5% from the quarter before. Operating margin was -31.7%, net loss $30.5M (29.4% of revenue).
Twist Bioscience, Q1 FY26: revenue $104M (+17% year over year), operating margin -31.7%, net loss $30.5M, operating cash flow −$24.8M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $104M | +5% | +17% |
| Operating profit | −$32.9M | — | — |
| Net earnings | −$30.5M | — | — |
| Operating cash flow | −$24.8M | — | — |
What changed
Revenue was $103.7M in Q1 FY26, up 17% year over year and up 5% from the previous quarter. NGS applications was the largest line at 51% of revenue. DNA synthesis and protein solutions added $11.0M year over year (up 27%), 73% of the total change.
Operating costs exceeded revenue by $32.9M, an operating margin of -31.7%. Total costs grew 11% against revenue growth of 17%. The fastest-growing cost line was SG&A (+24%). The quarter ended with a net loss of $30.5M, wider than the previous quarter's $27.1M loss.
Operating cash flow was −$24.8M. Non-cash charges added back $6.2M of depreciation and amortization and $13.3M of share-based compensation. Working capital and other items used $13.8M. Capital expenditures of $10.0M exceeded it, leaving free cash flow of −$34.8M.
Questions
What was Twist Bioscience's revenue in the first quarter fiscal 2026?
Twist Bioscience (TWST) reported revenue of $104M for the first quarter fiscal 2026 (Q1 FY26), +17% from a year earlier and +5% from the quarter before.
Was Twist Bioscience profitable in the first quarter fiscal 2026?
Operating loss was $32.9M (-31.7% of revenue) and net loss $30.5M.
Source: Twist Bioscience 10-Q on SEC EDGAR.